DODevon G. O’CAllaghan

Devon G. O’CAllaghan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Devon G. O’CAllaghan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Adam W. Avery

    Department of Chemistry, Oakland University, Rochester, MI 48309, USA

    1 shared publication
  • Brennon L. O’CAllaghan

    Department of Laboratory Medicine and Pathology, Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA

    1 shared publication
  • Emma Cismas

    Department of Chemistry, Oakland University, Rochester, MI 48309, USA

    1 shared publication
  • Harry T. Orr

    Department of Laboratory Medicine and Pathology, Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA

    1 shared publication
  • Jared Lamp

    Integrated Mass Spectrometry Unit, Department of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA

    1 shared publication
  • Matthew T. Thiel

    Department of Chemistry, Oakland University, Rochester, MI 48309, USA

    1 shared publication

Latest Publications

  • Open Access

    Impaired motor activity in a CRISPR SCA5 L253P knock-in mouse is associated with selective β-III-spectrin subcellular redistribution in the cerebellum

    by Adam W. Avery, Brennon L. O’CAllaghan, Matthew T. Thiel, Sarah A. Denha, Devon G. O’CAllaghan, Emma M. Cismas, Jared Lamp, Harry T. Orr, Thomas S. Hays

    The spinocerebellar ataxia type 5 (SCA5) L253P mutation in β-III-spectrin causes high-affinity actin binding. Here we developed a CRISPR knock-in mouse to determine the i n vivo impact of L253P on Purkinje neurons and motor activity, and to establish a model for future testing of SCA5 therapeutics. Significantly, the knock-in mouse shows impaired motor activity on elevated beam assays at 20 weeks. In the cerebellum, L253P causes a subcellular redistribution of β-III-spectrin in Purkinje neurons. This is marked by loss of β-III-spectrin in distal dendrites, accumulation of β-III-spectrin at the plasma membrane of the soma and proximal dendrites, and formation of inclusions in the soma. The inclusions additionally contain F-actin and α-II-spectrin, accumulate around the nucleus, form at an early age, and are larger in homozygous β-III-spectrin L253P/L253P compared to heterozygous β-III-spectrin L253P/+ mice. In contrast, neurons of the hippocampus and cerebral cortex, where β-III-spectrin is also known to be expressed, abnormally accumulate β-III-spectrin at the plasma membrane but do not form inclusions. To gain greater insight into disease mechanisms, unbiased proteomics identified over 150 cerebellar proteins that physically associate with β-III-spectrin. Of these, cluster analysis revealed a group of 41 proteins, including glutamate receptors, SERCA2, and CaMKII, linked to synaptic transmission. Thus, the effect of the L253P to alter β-III-spectrin localization, including decreased levels in distal dendrites, is likely associated with a disruption of β-III-spectrin function in postsynaptic signaling. Consistent with this, and in agreement with prior findings in knockout mice, the L253P β-III-spectrin knock-in mouse here shows that CaMKII, a calcium sensor and key mediator of glutamate signaling, is ~2-fold activated. Further, the abundance of EAAT4, a glutamate transporter, is significantly reduced. The L253P knock-in mouse primes future preclinical testing of SCA5 therapeutics, such as small molecule modulators of spectrin-actin binding, and glutamate and calcium signaling pathways.